Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

Thomas, A, Virdee, PS, Eatock, M et al. (10 more authors) (2020) Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. European Journal of Cancer, 124. pp. 131-141. ISSN 0959-8049

Abstract

Metadata

Authors/Creators:
  • Thomas, A
  • Virdee, PS
  • Eatock, M
  • Lord, SR
  • Falk, S
  • Anthoney, DA
  • Turkington, RC
  • Goff, M
  • Elhussein, L
  • Collins, L
  • Love, S
  • Moschandreas, J
  • Middleton, MR
Copyright, Publisher and Additional Information: © 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Oesophagogastric cancer; Dual erbB inhibitor; AZD8931
Dates:
  • Accepted: 13 October 2019
  • Published (online): 22 November 2019
  • Published: January 2020
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 07 Feb 2020 11:43
Last Modified: 07 Feb 2020 11:43
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.ejca.2019.10.010

Share / Export

Statistics